explore -WSS

explore

author：explore 2025-10-01 18:33:06 - browse：9

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview.

This abstract, presented by cancer researcher Qi Zhang of Zhejiang University School of Medicine, is yet another significant showing by AstraZeneca at this ASCO. The company had two plenary presentations on its blockbuster lung cancer drug Tagrisso and immunotherapy drug Imfinzi — as well as new results on Enhertu, which AstraZeneca developed with Daiichi Sankyo.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Ebola: Gilead Sciences antiviral shows promise as new treatment

WSS

The unintended consequences of overturning Roe v. Wade

As AI in medicine takes off, can 'human in the loop' prevent harm?

Chamber of Commerce, DOJ clash in court over drug prices

'A game

UCLA team creates talking throat patch for voice disorders

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

As demand for Covid shots wanes, Moderna seeks its next success

HHS secretary Becerra pressed on Change HealthCare cyberattack

In Memoriam: Notable people who died in 2023

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

The cancer drug shortage isn’t new — and neither are the solutions

What happened to the House vote on health price transparency?

What does generative AI mean for health care? We asked experts

President Biden's budget: Here's what you might have missed

Anesthesiologist group: stop taking Ozempic before surgery

David Liu startup to focus on CRISPR delivery

Wikipedia

RaDonda Vaught links Vanderbilt hospital issues to patient death

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

People with substance use disorder deserve online privacy

Fed up with FDA, ALS advocates consider a take

White House Covid adviser calls on docs to combat misinformation

How to save health care price transparency rules

focus

hotspot

hotspot

hotspot